E. Grabczak (Warszawa, Poland), C. Brightling (Leicester (Leicestershire), United Kingdom)
Including the ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials), these formats showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, session chairs and viewers will take part lively discussions on the presented trials.
Phase 3 RCT of C5a-Specific Vilobelimab in Severe COVID-19 Pneumonia
A. Vlaar (Amsterdam, Netherlands), G. Hermans (Leuven, Belgium), M. Witzenrath (Berlin, Germany), P. Van Paassen (Maastricht, Netherlands), L. Heunks (Amsterdam, Netherlands), B. Mourvillier (Reims, France), S. De Bruin (Amsterdam, Netherlands), E. Lim (Amsterdam, Netherlands), M. Piagnerelli (Charleroi, Belgium), A. Roquilly (Nantes, France), J. Lascarrou (Nantes, France), M. Bauer (Jena, Germany), C. Schwebel (Grenoble, France), M. Brouwer (Amsterdam, Netherlands), P. Tuinman (Amsterdam, Netherlands), T. Welte (Hannover, Germany), G. Marx (Leuven, Belgium), U. Jaschinski (Augsburg, Germany), A. Cornet (Enschede, Netherlands), A. Grebenyuk (Barnaul, Russian Federation), P. Jorens (Antwerp, Belgium), S. Rückinger (Munich, Germany), K. Pilz (Jena, Germany), C. Thielert (Jena, Germany), D. Neukirchen (Jena, Germany), L. Ruckerbauer (Munich, Germany), B. Burnett (Ann Arbor, United States), R. Guo (Ann Arbor, United States), D. Van De Beek (Amsterdam, Netherlands), N. Riedemann (Jena, Germany)
|    |
A randomised controlled trial of early intervention with oral favipiravir in patients hospitalised with COVID-19 (PIONEER Trial)
C. Orton (London, United Kingdom), P. Shah (London, United Kingdom), B. Grinsztejn (Rio de Janeiro, Brazil), G. Donaldson (London, United Kingdom), B. Crabtree Ramírez (Mexico City, Mexico), J. Tonkin (London, United Kingdom), B. Santos (Porto Alegre, Brazil), S. Cardoso (Rio de Janeiro, Brazil), A. Ritchie (London, United Kingdom), F. Conway (London, United Kingdom), M. Riberio (Rio de Janeiro, Brazil), D. Wiseman (London, United Kingdom), A. Tana (London, United Kingdom), B. Vijayakumar (London, United Kingdom), C. Caneja (London, United Kingdom), C. Leaper (London, United Kingdom), B. Mann (London, United Kingdom), A. Samson (Hull, United Kingdom), P. Bhavsar (London, United Kingdom), M. Boffito (London, United Kingdom), M. Johnson (London, United Kingdom), A. Pozniak (London, United Kingdom), M. Pelly (London, United Kingdom)
| |
Dipeptidyl Peptidase-1 Inhibition in Patients Hospitalized with COVID-19: a Multicentre Randomized Double-Blind Placebo Controlled Trial
H. Keir (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), H. Abo-Leyah (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), T. Pembridge (Dundee, United Kingdom), R. Hull (Sheffield, United Kingdom), L. Delgado (Dundee, United Kingdom), M. Band (Dundee, United Kingdom), F. Mclaren-Neil (Dundee, United Kingdom), S. Adamson (Dundee, United Kingdom), E. Lahnsteiner (Dundee, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), B. New (Dundee, United Kingdom), D. Connell (Dundee, United Kingdom), R. Dowey (Sheffield, United Kingdom), H. Turton (Sheffield, United Kingdom), H. Richardson (Dundee, United Kingdom), D. Cassidy (Dundee, United Kingdom), J. Cooper (Aberdeen, United Kingdom), J. Suntharalingam (Bath, United Kingdom), L. Diwakar (Stoke-on-Trent, United Kingdom), P. Russell (Harlow, United Kingdom), J. Underwood (Cardiff, United Kingdom), A. Hicks (Portsmouth, United Kingdom), D. Dosanjh (Birmingham, United Kingdom), B. Sage (Inverness, United Kingdom), D. Dhasmana (Kirkcaldy, United Kingdom), M. Spears (Dundee, United Kingdom), A. Thompson (Sheffield, United Kingdom), C. Brightling (Leicester, United Kingdom), A. Smith (Wishaw, United Kingdom), M. Patel (Wishaw, United Kingdom), J. George (Dundee, United Kingdom), A. Condliffe (Sheffield, United Kingdom), A. Shoemark (Dundee, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients Hospitalised Due to COVID-19 (NCT04732949)
P. Monk (Southampton, United Kingdom), J. Brookes (Southampton, United Kingdom), V. Tear (Southampton, United Kingdom), T. Batten (Twickenham, United Kingdom), M. Mankowski (Wokingham, United Kingdom), M. Kraft (Tucson, United States), C. Brightling (Leicester, United Kingdom), F. Gabbay (Wokingham, United Kingdom), S. Holgate (Southampton, United Kingdom), R. Djukanovic (Southampton, United Kingdom), T. Wilkinson (Southampton, United Kingdom)
| |
Wrap-up by discussant and discussion
A. Simonds (London, United Kingdom)
| |
Randomized, Double Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
I. Rosas (Houston, United States), J. Solomon (Denver, United States), S. Donoff (Baltimore, United States), F. Woodhead (Leicester, United Kingdom), G. Raghu (Seattle, United States), G. Hilary (Boston, United States), T. Network Investigators (NETWORK, United States)
| |
Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial
R. Deterding (Aurora, CO, United States), L. Young (Philadelphia, PA, United States), E. Deboer (Aurora, CO, United States), D. Warburton (Los Angeles, CA, United States), S. Cunningham (Edinburgh, UK, United Kingdom), N. Schwerk (Hannover, Germany), K. Flaherty (Ann Arbor, MI, United States), K. Brown (Denver, CO, United States), M. Dumistracel (Ingelheim am Rhein, Germany), E. Erhardt (Biberach, Germany), J. Bertulis (Biberach, Germany), M. Gahlemann (Basel, Switzerland), S. Stowasser (Ingelheim am Rhein, Germany), M. Griese (Munich, Germany)
| |
Wrap-up by discussant and discussion
K. Antoniou (Heraklion, Greece)
| |